GSK Shares Fall Despite Earnings Beat on Vaccine Sales Worry
GSK stock dropped sharply Wednesday as weak RSV and shingles vaccine demand overshadowed better-than-expected core earnings results.
Shares in GSK declined sharply on Wednesday, making the British pharmaceutical giant one of the biggest fallers on the FTSE 100, even as the company posted quarterly financial results that topped analyst forecasts. Investor concern centered on sluggish sales of vaccines targeting respiratory syncytial virus and shingles, as well as underperformance from recently introduced medicines.
The UK drugmaker reported a 19% drop in pre-tax profit to £1.9 billion for the July-to-September quarter, alongside £318 million in restructuring charges, with the company signaling that additional charges are forthcoming. The results underscored ongoing cost pressures within the organization as it works through a broader operational overhaul.
Read more Why Wall Street Stays Calm During Slow Midterm Vote Counts →
Despite the headline profit decline, core operating profit and core earnings per share rose 5% and 1% respectively, clearing the bar set by market analysts. The divergence between statutory and core figures reflects how restructuring costs are weighing on reported earnings while underlying business performance remains relatively stable.
The sell-off illustrates how markets can penalize companies even on positive earnings days when specific revenue drivers disappoint. For GSK, vaccines represent a strategically important growth pillar, and any softness in that segment draws outsized scrutiny from investors monitoring the company's post-separation trajectory following the spin-off of its consumer health division. The stock's reaction signals that Wall Street and the City remain focused on top-line vaccine momentum rather than cost-adjusted earnings metrics alone.
Continue reading at Business | The Guardian.
